Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Investment Type: Venture Capital
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| 02.04.2026 | 上海阶梯医疗科技有限... | stairmed.com | $500M | China |
| 22.09.2025 | Avenzo The... | avenzotx.com | $210M | United Sta... |
| 06.09.2025 | Ronovo Sur... | ronovosurgical.com | $161M | China |
Mentions in press and media 20
| Date | Title | Description |
| 03.04.2026 | China's BMI Frontier: StairMed Fuels Next-Gen Human-Machine Integration | StairMed secured RMB 500 million ($69M) from Alibaba, Tencent, and others. This investment accelerates brain-machine interface (BMI) and neuromodulation development. The company progresses 256-channel BMI clinical trials in China, pioneerin... |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 02.04.2026 | StairMed: RMB 500 Million (About $69 Million) Raised For Brain Machine Interface Development | Shanghai-based StairMed has secured RMB 500 million in a new financing round led by Alibaba, with participation from existing investors including Tencent, Fountainbridge Capital, OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Vent... |
| 22.03.2026 | Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies | Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling si... |
| 18.03.2026 | Excalipoint Therapeutics: $68.7 Million Raised For Next-Generation T-Cell Engager Therapies | Excalipoint Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell engager therapies, announced the close of an oversubscribed $68.7 million seed financing round to advance its proprietary platforms and pipel... |
| 13.03.2026 | Alibaba leads RMB 500 million investment in BCI startup StairMed | StairMed, a brain-computer interface (BCI) developer, has secured RMB 500 million (USD 72.7 million) in a funding round led by Alibaba Group, with participation from SDIC Unity Capital. Existing investors including Tencent, FountainBridge C... |
| 17.11.2025 | Chinese Drugmakers Rush to List in Hong Kong Amid Strong Investor Interest | (Yicai) Nov. 17 -- Chinese drugmakers are flocking to list in Hong Kong this year, driven by strong investor interest, recent stock market gains, overseas licensing deals, and regulatory reforms, though cornerstone investors are becoming mo... |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding. The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
Show more